Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: Insights from the PREDICTIVE study

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2601-2608

  Hermansen, Kjeld ^a   Dornhorst, Anne ^b   Sreenan, Seamus ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Stroke and Hypertension Unit   (Ireland)

Author keywords

Diabetes; Glycaemic control; Hypoglycaemia; Insulin aspart; Insulin detemir; Observational study

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; BOLUS INJECTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; TREATMENT OUTCOME;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 72549093542     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903262885     Document Type: Article

References (22)

1. Nathan DM, Buse JB, Davidson MB. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972 (Pubitemid 44156663)
2. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl. 1):S12-S54
3. Guideline for Management of Postmeal Glucose. Brussels: IDF, 2007. Available at: http://www.idf.org/webdata/docs/Guideline-PMG-final.pdf [Last accessed 23 December 2008]
4. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl. 3):S18-24 (Pubitemid 35034478)
5. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318(19):1231-1239 (Pubitemid 18120885)
6. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998;21(11):1904-1909 (Pubitemid 28478291)
7. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-629 (Pubitemid 38658363)
8. Rašlová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66(2):193-201. Corrigendum: Diabetes Res Clin Pract 2006;72:112 (Pubitemid 39469347)
9. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006;23(3):285-292
10. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26(3):799-804
11. Luddeke H-J, Sreenan S, Aczel S, et al. PREDICTIVE(TM): a global, perspective observational study to evaluate insulin detemir treatment in type 1 or type 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428-434 (Pubitemid 46502063)
12. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-596 (Pubitemid 36929312)
13. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes; a randomised clinical trial. Diabetes Care 2004;27:1081-1087 (Pubitemid 38579770)
14. Kølendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006;23:729-735 (Pubitemid 44366070)
15. Dornhorst A, Luddeke H-J, Sreenan S, et al. on behalf of the PREDICTIVE study group. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study. Int J Clin Pract 2008;62(4):659-665 (Pubitemid 351348041)
16. Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26(5):724-736 (Pubitemid 38736962)
17. Pieber TR, Draeger E, Kristensen A, et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-857 (Pubitemid 40942581)
18. Sreenan S, Virkamäki A, Zhang K, et al. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study. IJCP 2008;62(12):1971-1980
19. Bartley PC, Bogoev M, Larsen J, et al. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008;25(4):442-449
20. Dornhorst A, Lüddeke HJ, Honka M, et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2008;24(2):369-376 (Pubitemid 351294387)
21. Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23(6):441-454
22. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006;7(3):325-343 (Pubitemid 43263250)